Christopher P. Cannon, MD, is an associate professor of medicine at Harvard Medical School in the cardiovascular division at Brigham and Women's Hospital in Boston. He is a senior investigator of the Thrombolysis in Myocardial Infarction (TIMI) Study Group, and over the past two decades has been the principal investigator for more than ten international clinical trials in the area of heart attacks and prevention. The trials include PROVE IT-TIMI 22, which showed that "lower is better" for cholesterol and changed international guidelines, and CLARITY-TIMI 28, which showed that giving heart attack patients clopidogrel (Plavix) can prevent future heart attacks.
